Nyxoah Appoints Scott Holstine as Chief Commercial Officer

Mont-Saint-Guibert, Belgium – Nyxoah SA, a medical technology company focused on innovative treatments for Obstructive Sleep Apnea (OSA), has appointed Scott Holstine as Chief Commercial Officer. Scott will lead Nyxoah's commercial operations to support the U.S. launch.

Scott brings over 26 years of experience in the medical device industry. He is recognized for his expertise in U.S. product launches and commercial organization leadership. A West Point graduate and former U.S. Army Captain, Scott holds an MBA from the University of Minnesota's Carlson School of Management.

Nyxoah anticipates FDA approval by the end of 2024. Olivier Taelman, CEO of Nyxoah, emphasized the importance of an experienced commercial leader to accelerate the U.S. go-to-market strategy. Scott's appointment is crucial in building a high-performing team to fulfill Nyxoah’s mission for OSA patients.